PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity

Multiple Sclerosis Journal

Volumn 17, Issue 7, 2011, Pages 794-807

  Cavone, Leonardo ^a   Aldinucci, Alessandra ^a   Ballerini, Clara ^a   Biagioli, Tiziana ^a   Moroni, Flavio ^a   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

dendritic cells; multiple sclerosis; PARP 1; relapsing remitting EAE

Indexed keywords

CYCLOSPORIN A; CYTOKINE; EPITOPE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OVALBUMIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; BONE MARROW; CELL COUNT; CELL CULTURE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DEMYELINATION; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LYMPH NODE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RELAPSE; REMISSION; SPINAL CORD; TH17 CELL;

EID: 79959493209     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511399113     Document Type: Article

References (43)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006 ; 7: 517-528 (Pubitemid 44036457)
2. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem. 2000 ; 275: 40974-40980 (Pubitemid 32054922)
3. Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 2008 ; 20: 294-302
4. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002 ; 54: 375-429
5. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 ; 4: 421-440 (Pubitemid 40704125)
6. Szabo C. Role of poly(ADP-ribose)synthetase in inflammation. Eur J Pharmacol. 1998 ; 350: 1-19
7. Berton G, Sorio C, Laudanna C, Menegazzi M, Carcereri De Prati A, Suzuki H. Activation of human-derived macrophages by interferon-y is accompanied by increase of poly(ADP-ribose) polymerase activity. Biochim Biophys Acta. 1991 ; 1091: 101-109
8. Le Page C, Sanceau J, Drapier JC, Wietzerbin J. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF-kB activation. Biochem Biophys Res Comm. 1998 ; 243: 451-457 (Pubitemid 28414045)
9. Ducrocq S, Benjelloun N, Plotkine M, Ben-Ari Y, Charriaut-Marlangue C. Poly(ADP-ribose) synthethase inhibition reduces ischemic injury and inflammation in neonatal rat brain. J Neurochem. 2000 ; 74: 2504-2511 (Pubitemid 30314227)
10. Mazzon E, Dugo L, De SA, Li JH, Caputi AP, Zhang J, Cuzzocrea S. Beneficial effects of GPI 6150, an inhibitor of poly(ADP-ribose) polymerase in a rat model of splanchnic artery occlusion and reperfusion. Shock. 2002 ; 17: 222-227
11. King SL, McNerney R, Withely GS, Johnstone AP. Differential role for ADP-ribosylation in gene expression during the activation of T lymphocytes by various stimuli. Immunology. 1989 ; 67: 258-262 (Pubitemid 19151481)
12. Weltin D, Picard K, Aupeix K, Varin M, Oth D, Marchal J, et al. Immunosuppressive activities of 6(5)-phenanthridinone, a new poly(ADP-ribose) polymerase inhibitor. Int J Immunopharmacol. 1995 ; 17: 265-271
13. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol. 2002 ; 137: 761-770 (Pubitemid 35404175)
14. Nasta F, Laudisi F, Sambucci M, Rosado MM and Pioli C. Increased Foxp3+ regulatory T cells in poly (ADP-ribose) polymerase-1 deficiency. J Immunol 2010; 184: 3470-3477.
15. Shockett P, Stavnezer J. Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching. J Immunol. 1993 ; 151: 6962-6976 (Pubitemid 24001071)
16. Aldinucci A, Gerlini G, Fossati S, Cipriani G, Ballerini C, Biagioli T, et al. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol. 2007 ; 179: 305-312 (Pubitemid 46986546)
17. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol. 2001 ; 3: 1035-1042 (Pubitemid 33130453)
18. Ha HC, Hester LD, Snyder SH. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A. 2002 ; 99: 3270-3275 (Pubitemid 34240621)
19. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem. 2003 ; 85: 306-317 (Pubitemid 36438327)
20. Chiarugi A. PARP-1: killer or conspirator? The suicide hypothesis revisited. Trends Pharmacol Sci. 2002 ; 23: 122-129
21. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci. 2002 ; 59: 1534-1553 (Pubitemid 35239308)
22. Kraus WL, Lis JT. PARP goes transcription. Cell. 2003 ; 113: 677-683 (Pubitemid 36724932)
23. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N- dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther. 2004 ; 310: 1053-1061 (Pubitemid 39108927)
24. Scott GS, Hake P, Kean RB, Virag L, Szabo C, Hooper DC. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimmunol. 2001 ; 117: 78-86 (Pubitemid 32595495)
25. Kauppinen TM, Suh SW, Genain CP, Swanson RA. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J Neurosci Res. 2005 ; 81: 190-198 (Pubitemid 41153332)
26. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol. 2009 ; 10: 958-964
27. Selvaraj V, Soundarapandian MM, Chechneva O, Williams AJ, Sidorov MK, Soulika AM, et al. PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. J Biol Chem. 2009 ; 284: 26070-26084
28. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002 ; 2: 85-95 (Pubitemid 37323232)
29. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med. 2005 ; 11: 335-339 (Pubitemid 40460563)
30. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol. 2007 ; 8: 172-180 (Pubitemid 46152648)
31. Banasik M, Komura H, Shimoyama M, Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem. 1992 ; 267: 1569-1575
32. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001 ; 7: 255-260
33. Carrillo A, Monreal Y, Ramirez P, Marin L, Parrilla P, Oliver FJ, et al. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res. 2004 ; 32: 757-766 (Pubitemid 38263068)
34. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010 ; 16: 406-412
35. McNerney R, Darling D, Johnstone AP. Differential control of proto-oncogene c-myc and c-fos expression in lymphocytes and fibroblasts. Biochem J. 1987 ; 245: 605-608
36. McNerney R, Tavasolli M, Shall S, Brazinski A, Johnstone AP. Changes of mRNA levels of poly(ADP-ribose) polymerase during activation of human lymphocytes. Biochim Biophys Acta. 2001 ; 1009: 185-187
37. Haddad M, Beray-Berthat V, Coqueran B, Palmier B, Szabo C, Plotkine M, et al. Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose) polymerase inhibitor, after permanent focal cerebral ischemia in mice. Eur J Pharmacol. 2008 ; 588: 52-57
38. Pirrotta V. The ways of PARP. Cell. 2004 ; 119: 735-736 (Pubitemid 40017678)
39. Lonskaya I, Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL, Soldatenkov VA. Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding. J Biol Chem. 2005 ; 280: 17076-17083 (Pubitemid 41389171)
40. Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL, Soldatenkov VA. Specific binding of poly(ADP-ribose) polymerase-1 to cruciform hairpins. J Mol Biol. 2005 ; 348: 609-615 (Pubitemid 40515673)
41. Platten M, Steinman L. Multiple sclerosis: trapped in deadly glue. Nat Med. 2005 ; 11: 252-253 (Pubitemid 40460548)
42. Mangas A, Covenas R, Geffard M. New drug therapies for multiple sclerosis. Curr Opin Neurol. 2010 ; 23: 287-292
43. Lewis C, Low JA. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Curr Opin Investig Drugs. 2007 ; 8: 1051-1056 (Pubitemid 350224330)